CSTL earnings
Castle Biosciences Inc. (CSTL) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the close of market on Wednesday, May 6, 2026. Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.Webcast DetailsThe live webcast can be accessed here: https://events.q4inc.com/attendee/621816679, or via the webcast link on the Investor Relation
- Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025."We closed out an outstanding year with a strong fourth quarter, reflecting the strength of our innovative test portfolio, disciplined execution and the dedication of the entire Castle team who continue to d
- Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/483643109, or via the webcast link on the Investor Relations page of the Company's website: htt
- Castle Biosciences Reports Third Quarter 2025 ResultsDelivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company's test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that
- Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2025, after the close of market on Monday, Nov. 3, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/153584002, or via the webcast link on the Investor Relations page of the Company's website:
- Castle Biosciences Reports Second Quarter 2025 ResultsDelivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2025."Following a strong first quarter, our team closed out a very successful second quarter that we believe continued to reflect th
- Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast
- Castle Biosciences Reports First Quarter 2025 ResultsQ1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. "We are pleased with the exceptional start to the year, marked by continued growth in test report volum
- Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/787806709, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast
- Castle Biosciences Reports Fourth Quarter and Full-Year 2024 ResultsFull-year 2024 revenue of $332 million, an increase of 51% compared to 2023 and above previously reported guidance Delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023 Year-end 2024 cash, cash equivalents and marketable investment securities of $293 million, a $50 million increase compared to 2023 Anticipate generating between $280-295 million in total revenue in 2025 Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended December 31, 2024. "Castle delivered an outst
- Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2024, after the close of market on Thursday, Feb. 27, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/686536610, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.asp
- Castle Biosciences Reports Third Quarter 2024 ResultsQ3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2024. "We are thrilled with our third quarter performance, which reflects the continued success of our growth initiatives and the dedication of our team," said Derek Maetzold, president and chief executive officer of Castle Biosciences.
- Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday, Nov. 4, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/435529710, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.as
- Castle Biosciences Reports Second Quarter 2024 ResultsQ2 2024 revenue increased 74% over Q2 2023 to $87 million Q2 2024 total test reports increased 49% over Q2 2023 Raising full-year 2024 revenue guidance to $275-300 million from $255-265 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2024. "We achieved another quarter of exceptional performance, thanks to the hard work of our talented team and strength of our innovative test portfolio," said Derek Maetzold, president and chief executive officer of Castle Biosciences.
- Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/952012940, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.
- Castle Biosciences Reports First Quarter 2024 ResultsQ1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $255-265 million from $235-240 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2024. "The first quarter marked an excellent start to the year with strong execution across the company, resulting in outstanding revenue and volume growth across our therapeutic areas," said Derek Maetzold, president and chief executive officer of Cas
- Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2024, after the close of market on Thursday, May 2, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/562496463, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.aspx. Please a
- Castle Biosciences Reports Fourth Quarter and Full-Year 2023 ResultsFull-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment securities of $243 million Two critical peer-reviewed publications in 2023 demonstrating an association with DecisionDx®-Melanoma testing and improved patient outcomes Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023. "2
- Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/610272350, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.as
- Castle Biosciences Reports Third Quarter 2023 ResultsQ3 2023 revenue increased 66% over Q3 2022 to $61 million Q3 2023 total test reports increased 52% over Q3 2022 Raising full year 2023 revenue guidance to at least $200 million from at least $180 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2023. "Our third quarter results were exceptional, demonstrating the strength of our business fundamentals and the innovative test portfolio we've built to provide patients and clinicians with actionable information to gui
- Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2023, after the close of market on Thursday, Nov. 2, 2023. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/479909909, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/defau
- Castle Biosciences Reports Second Quarter 2023 ResultsQ2 2023 revenue increased 44% over Q2 2022 to $50 million Q2 2023 total test reports increased 52% over Q2 2022 Raising full year 2023 revenue guidance to at least $180 million from $170-180 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2023. "Castle delivered an outstanding second quarter, with strength across our entire test portfolio," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Building on our first quarter momentum and dr
- Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2023, after the close of market on Wednesday, Aug. 2, 2023. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/543951973, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/defau
- Castle Biosciences Reports First Quarter 2023 ResultsQ1 2023 revenue increased 57% over Q1 2022 to $42 million Q1 2023 total test reports increased 73% over Q1 2022 Reaffirming full-year 2023 revenue is expected to be between $170-180 million Conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2023. "Castle delivered a strong start to the year," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Building on our strength and momentum from 2022, we delivered significant test report volume and revenue growth in the f
- Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2023, after the close of market on Wednesday, May 3, 2023. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/614563599, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.aspx. Please
- Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/697513364 or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.aspx. Pl
- Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2022, after the close of market on Wednesday, Nov. 2, 2022. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/748805907 or via the webcast link on the Investor Relations page of the Company's website, https://ir.castlebiosciences.com/overview/default.
- Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2022, after the close of market on Monday, Aug. 8, 2022. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/949303499 or via the webcast link on the Investor Relations page of the Company's website, https://ir.castlebiosciences.com/overview/default.aspx
- Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2022, after the close of market on Monday, May 9, 2022. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://event.on24.com/wcc/r/3730612/6B0792D8D2EC88C9C59F5A12F812279B or via the webcast link on the Investor Relations page of the Company's website, https://ir.castlebiosciences.com/overview/de
- Castle Biosciences to Acquire AltheaDxFurthers mid- and long-term growth with strategic advance into pharmacogenomics and mental health Castle executive management to host conference call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that are focused on mental health. IDgenetix® is its PGx test for depression, anxiety and other mental health conditions. "As a company, we focus on transforming disease man
- Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022Castle Biosciences, Inc. (NASDAQ:CSTL), a leader in transforming disease management and improving patient outcomes through innovative diagnostics, today announced that it will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://event.on24.com/wcc/r/3574576/969E1FF81B791B8705198534F60A01D4 or via the webcast link on the Investor Relations page of the Company's website, htt
- Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021Castle Biosciences, Inc. (NASDAQ:CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2021, after the close of market on Monday, Nov. 8, 2021. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://www.incommglobalevents.com/viewer/14309/castle-biosciences-q3-2021-earnings-call/ or via the webcast link on the Investor Relations page
- Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021Castle Biosciences, Inc. (NASDAQ:CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, after the close of market on Monday, Aug. 9, 2021. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details A live webcast of the conference call can be accessed here: https://event.on24.com/wcc/r/3315443/658722E54799C7564600E9B3CB3E3EAE or via the webcast link on the Investor Relations page of the Company's websi
- Castle Biosciences Announces Fourth Quarter and Full-Year 2020 ResultsFRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2020. “Our execution in 2020 allowed us to successfully navigate through this unique year and further our position as the leader in genomic testing for dermatologic cancers,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We began the year with one skin cancer test and ended the year with a suite of three tests, more than tripling our estimated in-market U.S. to